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Abstract There is growing interest in the use of the ketogenic
diet (KD) to treat inherited metabolic diseases including mi-
tochondrial disorders. However, neither the mechanism
whereby the diet may be working, nor if it could benefit all
patients with mitochondrial disease, is known. This study
focusses on decanoic acid (C10), a component of the medium
chain triglyceride KD, and a ligand for the nuclear receptor
PPAR-γ known to be involved in mitochondrial biogenesis.
The effects of C10 were investigated in primary fibroblasts
from a cohort of patients with Leigh syndrome (LS) caused
by nuclear-encoded defects of respiratory chain complex I,
using mitochondrial respiratory chain enzyme assays, gene
expression microarray, qPCR and flow cytometry. Treatment
with C10 increased citrate synthase activity, a marker of cel-
lular mitochondrial content, in 50 % of fibroblasts obtained
from individuals diagnosed with LS in a PPAR-γ-mediated
manner. Gene expression analysis and qPCR studies sug-
gested that treating cells with C10 supports fatty acid metab-
olism, through increasing ACADVL and CPT1 expression,
whilst downregulating genes involved in glucose metabolism
(PDK3, PDK4). PCK2, involved in blocking glucose metab-
olism, was upregulated, as was CAT, encoding catalase.
Moreover, treatment with C10 also decreased oxidative stress
in complex I deficient (rotenone treated) cells. However, since
not all cells from subjects with LS appeared to respond to C10,
prior cellular testing in vitro could be employed as a means for
selecting individuals for subsequent clinical studies involving
C10 preparations.
Introduction
Mitochondrial diseases are the most common group of
inherited metabolic disorders, affecting approximately
1:5000 people (Thorburn 2004). They are unusually hetero-
geneous diseases, both phenotypically and genetically, and
can present at virtually any age and with any symptom or
combination of symptoms. To date >200 mitochondrial
DNA (mtDNA) and nuclear-encoded genes have been linked
to mitochondrial disorders (Rahman 2013). Leigh syndrome,
also known as subacute necrotising encephalomyelopathy, is
the most severe form of mitochondrial disease. Patients usu-
ally present in late infancy or early childhood, with progres-
sive neurological abnormalities. Symptoms include respirato-
ry abnormalities, nystagmus, ataxia, dystonia and hypotonia
(Fassone and Rahman 2012; Leigh 1951). Diagnosis of Leigh
syndrome requires the presence of characteristic clinical fea-
tures, increased lactate in blood and/or cerebrospinal fluid,
and the appearance of characteristic bilateral symmetrical
hyperintensities in the basal ganglia and/or brainstem in T2-
weighted magnetic resonance image sequences (Fassone and
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Rahman 2012; Rahman et al 1996). Leigh syndrome is itself
genetically heterogeneous, with causative mutations found in
genes encoded by the mtDNA, 14 nuclear-encoded subunits
of complex I (Fassone and Rahman 2012), and numerous
other genes (Lake et al 2015). Despite many advances made
in understanding the molecular causes of mitochondrial dis-
eases, treatment options are still very limited and mainly rely
on alleviation of symptoms (Kanabus et al 2014).
The ketogenic diet (KD), a high fat, low carbohydrate diet
used to treat drug-resistant epilepsy for decades, has been
investigated previously as a potential treatment for patients
with mitochondrial diseases. In cybrid cell lines containing
mtDNA deletions, the KD was shown to induce a
heteroplasmy shift in favour of wild-type mtDNA (Santra et
al 2004). Studies in animal models also showed that the KD
can trigger various beneficial cellular changes. Increased mi-
tochondrial respiration, decrease of reactive oxygen species
(ROS), upregulation of expression of uncoupling proteins
(Sullivan et al 2004), and increase of glutathione and lipoic
acid levels (Jarrett et al 2008) were observed in mice fed with
the KD. In the Deletor mouse (a mouse model for mitochon-
drial diseases, with mutations in the Twinkle helicase which
results in multiple mtDNA deletions) a decrease in COX-
negative fibres, improved mitochondrial ultrastructure and in-
creased mitochondrial biogenesis were also observed (Ahola-
Erkkila et al 2010). The few clinical reports of the use of KD
or high fat diet in complex I deficiency noted improvement in
seizures (Kang et al 2006; Seo et al 2010; Yoon et al 2014),
and transient improvement of oculomotor palsy in one patient
with early-onset Leigh-like syndrome due to NDUFV1 muta-
tions (Laugel et al 2007). However, long-term follow up and
treatment of larger cohorts has not been reported, and formal
clinical trials are required to provide evidence of efficacy
(Rahman 2012).
The KD mechanism of action remains poorly understood,
despite its use in clinical settings for decades. Proposed mech-
anisms include alterations in mitochondrial antioxidant status
(Jarrett et al 2008), modulation of neurotransmitter levels (e.g.
gamma-aminobutyric acid, GABA) (Yudkoff et al 2004) and
changes to cellular energy metabolism accompanied by mito-
chondrial biogenesis (Bough et al 2006). The medium-chain
triglyceride (MCT) diet is a variation of the classic KD. It is as
effective in treating seizures as the classic KD, which mostly
consists of long-chain fats. In the classic KD approximately
80% of total caloric intake is fat derived, whereas in the MCT
diet this proportion can be reduced to 60 % (Neal et al 2009),
and it predominantly contains octanoic acid and decanoic ac-
id, which are also observed in increased levels in the plasma of
individuals on this diet (Haidukewych et al 1982).
Recently decanoic acid (C10) was reported to be a ligand
for the nuclear receptor PPAR-γ which is known to be in-
volved in mitochondrial biogenesis (Malapaka et al 2012).
Furthermore C10 has been shown to induce mitochondrial
biogenesis and increase complex I and catalase activity in a
neuronal cell line (Hughes et al 2014). In light of very few
promising treatments on the horizon for primary mitochondri-
al disorders (Kanabus et al 2014), we sought to determine the
effects of C10 treatment on mitochondrial function in primary
fibroblasts from a cohort of individuals with nuclear-encoded
complex I deficient Leigh syndrome (Table 1 & Fig. 1a).
Materials and methods
Cell culture and treatment
Skin biopsies for fibroblast culture from affected research par-
ticipants (herein also referred to as subjects) were performed
after informed parental consent including consent for research
studies. This study received ethical approval from the
National Research Ethics Committee London Bloomsbury,
UK. Subject 2 cells are fetal cells.
For citrate synthase, complex I and complex IV assays,
human skin fibroblast cells (passage 8–15) from controls
and subjects were maintained in 182 cm2 flasks at 37 °C,
5 % CO2 in Dulbecco’s Modified Eagle’s Medium
(DMEM), containing 25 mM glucose, 3.97 mM L-
Glutamine and supplemented with 10 % heat inactivated fetal
bovine serum (FBS, Invitrogen), 50 mg/L uridine and 100 μg/
ml penicillin/streptomycin.
For treatment with C10, 100 μl of 50 mM C10 in DMSO
(which functioned as the delivery vehicle for C10) was added
to 20 ml of supplemented DMEM to a final concentration of
250 μM C10. This concentration was determined as optimal
through a dose response curve (data not shown). Untreated
fibroblasts were incubated with 100 μl of DMSO alone. All
Table 1 Genetic defects of cell lines investigated in this study
Sample Mutated gene Biochemistry
Complex I activity measured
in muscle (normalised to CS
activity) (reference range
0.104–0.268) [% mean control]
Patient 1a NDUFV1 0.063 [34 %]
Patient 2ac NDUFV1 ND
Patient 3b NDUFV2 0.067 [36 %]
Patient 4b NDUFV2 ND
Patient 5 NDUFS2 ND
Patient 6 NDUFS4 0.052 [28 %]
a patients 1 and 2 are siblings
b patients 3 and 4 are siblings
c fetal cells; ND not determined (because patients 2 and 4 were siblings of
cases who had already been diagnosed, and patient 5 presented before
respiratory chain assays were routinely performed in muscle)
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treatments lasted 6 days, with one medium change on day 3. A
6 day incubation with decanoic acid was chosen since it was
found to be the optimal time of treatment in time course ex-
periments previously reported by our group (Hughes et al
2014). For some incubations with 250 μM C10, Bisphenol
A diglycidyl ether (BADGE, Tocris Bioscience, Bristol,
UK), a PPAR-γ antagonist, was added to a final concentration
of 25 μM (Hughes et al 2014). Effects of supplementing cells
for 6 days with the ketone bodies β-hydroxybutyrate (BHB)
or acetoacetate (ACA), both at a final concentration of 5 mM
(levels seen in blood of patients on KD) were also
investigated.
For L-lactic acid quantification, fibroblasts were grown in
six well tissue culture plates and maintained in 2 mL of non-
phenol red DMEM medium, containing 25 mM glucose,
3 . 9 7 mM L - G l u t a m i n e a n d 2 5 mM N - 2 -
hydroxyethylpiperazine-N-2-ethane sulphonic acid
(HEPES). DMEM was supplemented with 10 % heat
inactivated fetal bovine serum (FBS), 100 μg/ml penicillin/
streptomycin (10U/μl penicillin G sodium, 10 μg/μl strepto-
mycin sulphate in 0.85 % saline) (Sigma), uridine (final con-
centration 50 mg/L) (Sigma) and sodium pyruvate (final con-
centration 1 mM) (Gibco). Cells were treated with C10 or
DMSO for 6 days, with one medium change on the third
day. On day 6, medium and treatment were changed again,
and cells incubated for a further 24 h.
Assays of citrate synthase, complex I and complex IV
activities
Citrate synthase (CS, EC 4.1.3.7) activity was determined
according to the method described by Shepherd and Garland
(1969), adjusted to be compatible with a 96-well microplate
reader. The reaction final volume was reduced to 200 μl. All
reaction substrates were proportionally reduced (see
Supplemental Methods for details). Sample protein concentra-
tion was measured using the Bradford method and adjusted to
1 mg/ml before CS activity determination.
Complex I (EC 1.6.5.3) and complex IV (EC 1.9.3.1) ac-
tivities were measured using the Complex I Enzyme Activity
Microplate Assay Kit and Complex IV Enzyme Activity
Microplate Assay Kit respectively (Abcam, Cambridge,
UK). Activities of both complexes were measured in whole
cell lysates, prepared according to manufacturer’s guidelines.
L-lactic acid quantification
L-Lactic acid was measured as described by (Gutmann and
Wahlefeld 1974), with several adjustments to allow measure-
ments in extracellular fluid from fibroblast cultures using a
plate reader system. 200 μl medium from each well was
deproteinised by centrifuging with 10 μl of 30 % ZnSO4 at
13,000 rpm for 10 min, and the supernatant was transferred
into a clean tube and kept on ice. The sample was diluted in
water 1:10, and 100 μl of the diluted sample was mixed with
100 μl of the reaction mixture (0.5 M Glycine (Sigma), 1 M
Hydrazine-HCl (Sigma), 2 mM EDTA (Sigma), pH 9.3, plus
2 % NAD (Sigma)) in a 96 well plate. Baseline absorbance
was measured at 340 nm in a Tecan 200 Pro plate reader; 5 μl
of lactate dehydrogenase (LDH, Roche) was added into each
well, and absorbance was read again 120 min later.
Absorbance values were normalised to the baseline
absorbance.
Mitochondrial volume, membrane potential and ROS
Mitochondrial volume, membrane potential and ROS were
measured by a FACS Calibur flow cytometer. Cells were
grown and treated for 6 days in 75 cm2 flasks. After comple-
tion of 6 day C10 treatment, cells were harvested using 0.05%
trypsin-EDTA and counted by FACS Calibur. To-Pro3 (Life
Technologies) at a final concentration of 0.05 nM was used to
determine cell viability. Staining with either MitoTracker
Green FM (final concentration 200 nM), TMRE (final con-
centration 600 nM), or MitoSox (final concentration 5 μM),
was used to measure mitochondrial volume, membrane poten-
tial or ROS respectively, per 50,000 cells. Cells were incubat-
ed with these stains in a 96-well plate for 15 min at 37 °C, 5 %
CO2. Cells were washed with PBS (10 % FBS), and resus-
pended in an equal volume of PBS (10 % FBS)+0.05nM To-
Pro3. Samples were protected from light and immediately
transferred onto a flow cytometer fitted with 488 nm wave-
length argon and 635 nm wavelength diode lasers. MitoSox
and TMRE emissionwas collected using the 585/42 band pass
filter (FL-2) and MitoTracker Green FM using the 530/30
band pass filter (FL-1). To-Pro-3 was measured using the
661/16 band pass (FL-4, red) filter. Data were collected using
CellQuest software (BD Biosciences, USA) on a minimum of
10,000 live events, and analysed using the FloJo v.10.0 soft-
ware (TreeStar, USA).
Mitochondrial resistance to rotenone induced oxidative
stress
Control 1 and subject 6 cells (chosen due to their strongest
increase in CS enzyme activity in response to treatment with
C10) were grown and treated with 250 μM C10 for 6 days in
75 cm2 flasks. On day 5 (24 h before harvesting), the cells
were treated with varied concentrations of rotenone, ranging
from 0 to 2000 nM in DMSO. Harvested cells were stained
with MitoSox at a final concentration of 5 μM and incubated
for 15 min at 37 °C, 5 % CO2. Cells were washed with PBS
(10 % FBS), and resuspended in an equal volume of PBS
(10 % FBS). Samples were protected from light and immedi-
ately transferred onto the flow cytometer. ROS was measured
by a LSR II flow cytometer (BD Biosciences). MitoSox
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emission was collected using the 575/26 nm (PE-TexasRed)
laser. Data were collected using the FACSDiva software (BD
Biosciences, USA) based on a minimum of 10,000 events.
Gene expression analysis using affymetrix GeneChip 1.0
ST microarray
Differential gene expression in control +DMSO compared
to C10 treated cells was analysed in control 1 fibroblasts
us ing the GeneChip Gene 1.0 ST Array System
(Affymetrix) according to the manufacturer’s guidelines.
Fibroblasts were grown in 75 cm2 cell culture flasks and
supplemented with C10 or DMSO (n= 6 C10 group, and
n= 5 control group) as described above. RNAwas extracted
using the RNeasy Plus Mini Kit (Qiagen), according to the
manufacturer’s instructions. Raw data were normalised ac-
cording to manufacturer’s protocols using the Expression
Console software. Upon normalizing, data were analysed
using GeneSpring GX software (Agilent Technologies).
Genes which had a >0.3 fold change in expression (i.e.
+/− 30 % of control) and a p< 0.05 were considered differ-
entially expressed.
Gene expression analysis using real-time PCR
Fibroblasts from control 1, subject 1 and subject 6 were cul-
tured in 75 cm2 cell culture flasks and supplemented with C10
or DMSO (n=3 for each group) as described above. RNAwas
extracted using the RNeasy Mini Kit (Qiagen) according to
the manufacturer’s protocol. GoScript Reverse Transcription
System (Promega) was used to make cDNA from an equal
amount of RNA in all samples. Relative quantification of ten
genes (CS, PPARG, PPARGC1A, NRF1, NRF2, ERRA, CAT,
ACADVL , HMOX1, TXNIP) was carried out using
PowerSYBR Green (LifeTechnologies) according to the man-
ufacturer’s guidelines and normalised to two housekeeping
genes, B2M and BACT. Primer sequences are provided in
Table S1. Data analysis was performed using StepOne
Software v2.3 (Applied Biosciences).
Statistical analysis
All results are expressed as mean ± standard error of mean
(SEM). The n number refers to the number of independent
cell culture preparations, all measured in duplicate or trip-
licate. Statistical analysis between two groups was per-
formed using the paired Student’s t-test, where the same
sample was compared (for example treated vs. untreated)
or using the unpaired t-test, when two different samples
were compared (subject vs. control). For multiple compar-
isons, a one-way ANOVA was used followed by a Tukey
post-hoc test. Any ratios were transformed ensuring a nor-
mal distribution. Results were considered significant when
p< 0.05.
Results
Increased citrate synthase activity in cells from controls
and research subjects following 6 day incubation
with decanoic acid
CS enzyme activity is a reliable biomarker of mitochondrial
enrichment (Larsen et al 2012). Here we measured CS activity
in eight independent primary fibroblast cell cultures exposed
to C10 for 6 days (Fig. 1b). We show that the two control
fibroblast cultures and six fibroblast cell cultures from six
research participants with complex I deficiency (Fig. 1a) re-
spond differently to a 6 day exposure to C10. Control cell
cultures both showed a significant increase in CS activity, as
did cells from three of the six research subjects following C10
treatment (Fig. 1b). CS was not increased following C10
treatment in fibroblasts from the remaining three subjects
(Table S2). Thus cells with different genetic defects appear
to respond differently to C10 treatment, even though the af-
fected patients have the same clinical and biochemical disease
(complex I deficient Leigh syndrome). CS activity was also
increased in fibroblasts from two subjects (subjects 2 and 6) in
response to 6 day incubation with BHB, while ACA appeared
to have no effect (Fig. S1).
Respiratory chain complex I and IVactivities and L-lactic
acid production
Our CS activity data suggested the possibility of mitochondri-
al content enrichment following C10 treatment. We next
Fig. 1 a Complex I activity measured in fibroblasts obtained from
healthy individuals or complex I deficient patients diagnosed with
Leigh syndrome. b Both control fibroblast samples showed a
significant increase in CS activity following C10 treatment. Fibroblasts
from subjects 1 and 2 (siblings, compound heterozygous NDUFV1
mutations) showed a varied CS response following C10 exposure. Cells
from subject 1 showed a significant increase in CS activity, whereas cells
from subject 2 did not. Subject 6 (homozygousmutation inNDUFS4) and
subjects 3 and 4 cells (sib-pair, with homozygous mutation in NDUFV2)
all showed a significant increase in CS activity following C10 treatment.
Subject 5 cells (with compound heterozygous mutations inNDUFS2) did
not show a change in CS enzyme activity. *p< 0.05, **p < 0.01. c CS
enzyme activities measured in control 1 fibroblast cells. Cells were
incubated with C10, BADGE or both C10+BADGE. Incubation with
C10 increased CS enzyme activity by 100 % compared to control.
Incubation with BADGE significantly decreased CS activity compared
to control, whereas co-incubation of BADGE+C10 restored CS activity
to control levels; d CS enzyme activities measured in subject 6 fibroblast
cells. Incubation with C10 increased CS enzyme activity by twofold.
Incubation with only BADGE did not have an effect on CS activity;
however, incubation with BADGE+C10 resulted in CS activity similar
to that obtained with just C10 incubation. *p < 0.05, **p < 0.01,
***p< 0.001
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sought to determine whether the respiratory chain complex
activities had changed after C10 treatment. Complex I enzyme
activity increased after C10 exposure in control 2 fibroblasts
but not in control 1 or any of the subject cells. Importantly we
did not observe any reduction in complex I activity in fibro-
blasts from either controls or subjects following C10 treat-
ment. Complex IV activity was only reduced in subject 6.
Neither ACA nor BHB had a consistent effect on control or
subject cell complex I and IVactivities. However, complex IV
activity decreased in cells from subjects 2, 4 and 6 following
both treatments (Fig. S2 and Table S2).
We also wished to determine whether C10 treatment had
any effect on L-lactic acid production. We observed no chang-
es in L-lactic acid production in either control or subject cells
(Fig. S3).
Citrate synthase activity following Co-incubation
with C10 and the PPAR-γ nuclear receptor antagonist
bisphenol A diglycidyl ether (BADGE)
Since C10 is a known PPAR-γ receptor agonist (Malapaka et
al 2012), we aimed to determine if the observed increase in CS
activity in control and subject fibroblasts was due to activation
of the PPAR-γ pathway. In control cells, we found that incu-
bation of fibroblasts with BADGE, a PPAR-γ receptor antag-
onist, reduced CS activity compared to untreated cells, or
those incubated with C10 alone. Furthermore, following co-
incubation of C10 and BADGE, CS activities were similar to
those in untreated cells (Fig. 1c). In subject 6 fibroblasts,
BADGE did not appear to have such a strong effect, and no
reduction in CS enzyme activity was observed between un-
treated cells and those incubated only with BADGE (Fig. 1d).
However, in cells treated with BADGE+C10, the CS enzyme
levels were as high as those cells treated only with C10
(Fig. 1d). Taken together, these observations suggest that in
cells from both controls and affected research participants the
increase in CS activity following C10 treatment is mediated
via the PPAR-γ pathway.
Mitochondrial volume, reactive oxygen species
and membrane potential following C10 treatment
We found that cells from most research subjects had a similar
mitochondrial volume when compared to controls (except
subject 4 cells which had a higher mitochondrial volume,
and subject 5, with a lower volume) (Fig. 2a). Incubation of
fibroblasts with C10 led to a significantly increased mitochon-
drial volume only in cells from subject 3 (Fig. 2a). Cells from
three subjects showed an increase in baseline ROS levels (sub-
jects 2, 4 and 6), compared to ROS levels in healthy control
cells (Fig. 2b). Following C10 treatment we found that ROS
levels increased significantly in cells from only one subject—
subject 3 (Fig. 2b), which also showed baseline increase in
mitochondrial membrane potential (Fig. 2c), but because the
overall mitochondrial volume in these cells was also increased
the ratio of ROS and membrane potential to mitochondrial
volume remained unaltered. Additionally an increase in mem-
brane potential was also noted in cells from control 2
(Table S2).
ROS production in rotenone treated cells and the effects
of C10
Based on our previously published finding that C10 increases
catalase activity (Hughes et al 2014), and our qPCR data
which showed that C10 increased the expression of CAT, we
aimed to determine whether C10 is able to increase cellular
resistance to oxidative stress. This experiment was carried out
in control cells, as well as cells from subject 6, as these were
the cells which showed the highest increase in CS activity in
response to C10. We found that treatment of both the control
and subject cells with C10 reduced the amount of ROS trig-
gered by the exposure of the cells to rotenone, but C10 did not
decrease ROS levels in cells not exposed to rotenone (Fig. 3).
Gene expression analysis
In order to better understand the mechanism of action by
which C10 is able to increase CS enzyme activity and to gain
a more global view of the effects of C10 on fibroblasts, we
performed a genome-wide gene expression microarray study.
Overall 521 genes had upregulated expression levels and 200
genes were downregulated. None of the common mitochon-
drial biogenesis genes (such as PPARG, PPARGC1A, NRF1,
NRF2, ESRRA) showed changes in expression levels at the
end of a 6 day incubation with C10. The entire list of genes
observed to have altered expression can be found in
Supplementary Table S3. Genes which where differentially
expressed in the two groups, and based on the MitoCarta
prediction are expected to encode mitochondrially targeted
proteins, are listed in Table 2.
In addition to analysing gene expression through a mi-
croarray study, relative quantification of genes known to be
invo lved in mi tochondr ia l b iogenes i s (PPARG ,
PPARGC1A, NRF1, NRF2, ESRRA) was also performed
using qPCR. Furthermore, three other genes were also
analysed through qPCR in order to validate the microarray
results (ACADVL and HMOX1, which were upregulated in
the microarray and TXNIP, which was downregulated). We
found that relative gene expression levels of these three
genes measured in control fibroblasts (the same cells which
were used in the microarray study), were in alignment with
the microarray data (Fig. S4). Finally, using qPCR we also
examined the expression of CAT, encoding catalase, and
found it to be increased in control cells. This was not ob-
served in the microarray (Fig. 4).
420 J Inherit Metab Dis (2016) 39:415–426
Interestingly, the gene expression levels varied between cells
from subjects 1 and 6. Subject 1 cells showed a significant in-
crease in relative expression levels of HMOX1, while no change
was observed in expression of TXNIP. In contrast, cells from
subject 6 showed no change inHMOX1 expression levels, while
TXNIP was significantly decreased upon a 6 day treatment with
C10. ACADVL and CAT expression was increased in cells from
both subjects 1 and 6 after treatment with C10 (Fig. S4).
Discussion and conclusions
Mitochondrial diseases, despite being the most common
group of inherited metabolic disease, are in the majority of
cases untreatable and often fatal diseases. Huge scientific ef-
forts are currently being directed towards developing new
treatment approaches. However, due to the large genetic and
phenotypic heterogeneity of these disorders, validation of new
Fig. 2 aMitochondrial volume:
compared to controls only subject
5 cells showed a reduction in
baseline mitochondrial volume.
Subject 4 fibroblasts had
increased baseline mitochondrial
volume compared to control. In
response to treatment with C10,
only fibroblasts from subject 3
showed a significant increase. b
Mitochondrial ROS: subjects 2
and 6 fibroblasts showed higher
baseline ROS levels when
compared to controls. Subject 5
cells had significantly lower
baseline ROS when compared to
controls. In response to treatment
with C10, only subject 3
fibroblasts showed an increase in
ROS. cMembrane potential:
when compared to control cells,
subjects 2, 3 and 6 fibroblasts all
had higher baseline membrane
potential. In response to treatment
with C10, control 2 and subject 3
cells showed an increase in
membrane potential. Subject 4
cells also appeared to have
increased membrane potential
when treated with C10; however,
this result was not statistically
significant. *p< 0.05, **p < 0.01,
***p< 0.001
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treatments through proper clinical trials is proving to be ex-
tremely challenging (Pfeffer et al 2012; Kanabus et al 2014).
Several treatment approaches under consideration aim to in-
crease mitochondrial biogenesis, for example Bezafibrate
(Yatsuga and Suomalainen 2012) and 5-amino-1-β-D-
ribofuranosyl-imidazole-4-carboxamide (AICAR)
(Golubitzky et al 2011). Recently our group proposed another
alternative, C10, as a potential activator of mitochondrial bio-
genesis (Hughes et al 2014). It is known that C10, a medium
chain fatty acid, is a PPAR-γ ligand (Malapaka et al 2012).
Our previous work demonstrated that in a neuronal cell model
(SHSY-5Y cells), C10 increased the activities of CS, complex
Fig. 3 Effects of C10 on mitochondrial oxidative stress. A 6 day
treatment with C10 reduced the oxidative stress of control and subject 6
fibroblasts exposed to various concentrations of rotenone for 24 h. C10
did not affect ROS levels in cells not exposed to rotenone. (n = 3;
*p< 0.05, **p< 0.01, ***p < 0.001)
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I and catalase (Hughes et al 2014). In view of these findings,
in this study we investigated whether C10 could have similar
beneficial effects in fibroblast cells obtained from subjects
with genetically confirmed primary mitochondrial diseases.
The enzyme CS is widely used as a biomarker for mito-
chondrial enrichment. It has been shown that CS activity has a
strong relationship with mitochondrial fractional area (Larsen
et al 2012). We observed an increase in CS activity in the
majority of fibroblasts upon incubation with 250 μM C10
for 6 days. Since CS enzyme is a marker for mitochondrial
enrichment, we examined overall mitochondrial volume using
MitoTracker Green FM staining. We found no significant
changes in all but one cell line— subject 3. This suggests that
the increase in CS activity may not necessarily be caused by
an increase in cellular mitochondrial volume. Furthermore,
microarray and qPCR results also did not show an increase
in expression levels ofCS, but a transient change in expression
levels may have occurred prior to day 6.
C10 has previously been shown to be a partial activator of
the PPAR-γ receptor (Malapaka et al 2012). More potent
PPAR-γ activators such as members of the thiazolidinedione
drug family (including rosiglitazone) may trigger serious side
effects including adipogenesis, stroke and myocardial infarc-
tion (Spiegelman 1998; Graham et al. 2010). C10 is a compo-
nent of the MCT diet, which is not associated with such ad-
verse effects. Additionally, it has been shown that C10 does
not increase glucose sensitivity, and improves the overall lipid
profile without having an effect on weight in diabetic mice
(Malapaka et al 2012). In order to confirm that the increase in
CS enzyme activity observed in cells supplemented with C10
is a downstream effect of PPAR-γ activation, we also mea-
sured CS activity in the presence of BADGE, a PPAR-γ
receptor antagonist (Fig. 1c and d). We found that incubating
control fibroblasts in the presence of BADGE reduced CS
activity levels significantly, while incubating these cells with
BADGE+C10 restored CS activity levels to control values.
These data confirm that the observed increase in CS activity
occurs as a result of a PPAR-γ mediated pathway, at least in
control cells. However, the observation of an attenuated re-
sponse to BADGE in one subject raises the possibility of
altered PPAR-γmediated signalling in some cases of complex
I deficiency.
It has been previously suggested that an increased mito-
chondrial content may be associated with reduced respira-
tory chain enzyme activities (Bernier et al 2002). Since we
were investigating the effects of C10 on cells obtained from
complex I deficient individuals, we measured complex I to
ensure that C10 does not have a detrimental effect on these
cells. Reassuringly, our results showed that C10 did not
exacerbate the complex I deficiency. Moreover, in control
2 cells, complex I activity was increased. Our previous
study performed on SHSY-5Y cells also found an increase
in complex I activity after treatment with C10 (Hughes et al
2014). Complex I is reported to be rate limiting for ATP
formation in neuronal cells but this may not be the case
for other cell types such as fibroblasts (Davey et al. 1998).
Furthermore, the glycolytic nature of fibroblasts plus the
genotype/phenotype of the affected subjects’ cells studied
may be contributing factors to the differences seen in this
study when compared to those previously performed on a
relatively homogeneous cell line.
C10 has a similar chemical structure to the anticonvulsant
valproic acid, which has also been linked to increased mito-
chondrial biogenesis (Hayasaka et al. 1986), and which has
Table 2 Mitochondrial genes
with differential gene expression
levels upon treatment with C10
Genes with upregulated expression levels following C10 treatment
Gene Function
PDK4 pyruvate dehydrogenase kinase, isozyme 4
PDK3 pyruvate dehydrogenase kinase, isozyme 3
GLYATL2 glycine-N-acyltransferase-like 2
ATP5O ATP synthase, H+ transporting, mitochondrial F1 complex, O subunit
CPT1A carnitine palmitoyltransferase 1A (liver)
ACADVL acyl-CoA dehydrogenase, very long chain
Genes with downregulated expression levels following C10 treatment
Gene Function
SLC25A23 solute carrier family 25 (mitochondrial carrier; phosphate carrier), member 23
PCK2 phosphoenolpyruvate carboxykinase 2
MTHFD2 methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2 and
methenyltetrahydrofolate cyclohydrolase
DHRS3 dehydrogenase/reductase (SDR family) member 3
NDUFC1 NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 1,
ALDH1L2 aldehyde dehydrogenase 1 family, member L2
ADHFE1 alcohol dehydrogenase, iron containing, 1
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been shown to reduce mitochondrial complex IV activity
(Ponchaut et al. 1995). It was therefore important also to mea-
sure complex IV activity following treatment of the control
and subject fibroblasts with C10. We observed a decrease in
complex IV activity only in one out of eight fibroblast cul-
tures, suggesting that C10 does not share valproate’s toxic
effects on mitochondrial respiratory chain function.
We further evaluated the effects of C10 on ROS levels and
mitochondrial membrane potential. Increased ROS levels are
thought to be one of the main pathogenic mechanisms under-
lying mitochondrial disorders, especially in patients with com-
plex I deficiencies, since complex I is a major site of mito-
chondrial ROS production. Any compound which increases
ROS levels could potentially cause further damage to the re-
spiratory chain (Heales et al. 1996; Marí et al. 2009). We
found that in all subject cells, except for subject 3, mitochon-
drial ROS levels were unchanged following C10 treatment.
Subject 3 cells also showed an increase in overall
Fig. 4 Effects of C10 on gene expression. A 6 day treatment with C10
reduced the expression of genes involved in glucose metabolism, such as
PCK2, which encodes phosphoenolpyruvate carboxykinase, an enzyme
important in the gluconeogenesis pathway. The complex I supernumerary
subunit NDUFC1 (of unknown function), was also reduced. Glucose is
metabolised to acetyl-CoA, which enters into the tricarboxylic cycle.
Electrons derived from the Krebs cycle enter oxidative phosphorylation
through complex I, as opposed to those derived through β-oxidation,
which bypass complex I and enter oxidative phosphorylation through
complex III. Additionally, PDK3 and PDK4 were upregulated. These
genes encode the enzyme pyruvate dehydrogenase kinase, which
inhibits the enzyme pyruvate dehydrogenase. Genes involved in fatty
acid metabolism upregulated after 6 day C10 treatment include CPT1A
(which encodes a protein responsible for fatty acid transport into
mitochondria) and ACADVL, which encodes the enzyme VLCAD
required for the metabolism of fatty acids with a chain length of 14–20
carbons. ATP50 (which encodes a subunit of ATP synthase) also showed
increased expression in response to treatment with C10
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mitochondrial volume, which might explain the observed in-
crease in ROS. Indeed, ROS levels per unit of mitochondrial
volumewere unchanged. Additionally, our qPCR experiments
revealed increased CAT expression levels in all three cell lines
studied, including the one which did not show an increase in
CS activity (i.e. cells from subject 1). These data are consistent
with our previous observation that C10 treatment increased
catalase enzyme activity in SHSY-5Y cells (Hughes et al
2014) and led us to suspect that C10 may increase cellular
resistance to oxidative stress. This hypothesis was confirmed
by the fact that cells treated with C10 and exposed to rotenone
had lower ROS levels than cells not treated with C10 but
exposed to the same concentration of rotenone. However, this
observation may also indicate an improvement of mitochon-
drial function as we have previously reported that ROS pro-
duction is more sensitive than ATP as an indicator of changes
in mitochondrial function (Jacobson et al 2005). We also ex-
amined mitochondrial membrane potential pre- and post-C10
treatment. Increasedmitochondrial membrane potential would
be suggestive of better proton pumping functions of the respi-
ratory chain complexes and increased ATP production. It is
important to note, however, that increased mitochondrial
membrane potential may result in increased ROS levels, and
vice versa, high ROS levels can lead to the depolarization of
the mitochondrial membrane potential (Korshunov et al.
1997). Furthermore, under certain conditions mitochondrial
membrane potential may be maintained at the expense of
ATP production, by reversal of the activity of the ATP syn-
thase (Duberley et al. 2013). Similarly to the ROS results, we
observed no changes in mitochondrial membrane potential in
cells from both controls and all studied subjects, except fibro-
blasts from subject 3, in which we also observed increased
mitochondrial volume, as discussed above.
Our microarray data also suggest that supplementation of
cell culture medium with C10 in the presence of high glucose
concentration upregulates genes involved in fatty acid metab-
olism, whilst downregulating expression of genes involved in
glucose metabolism (Table 2, Fig. 4). Upregulation of genes
such as LDLR, CPT1A and ACADVL suggests that lipid me-
tabolism pathways are overall upregulated without discrimi-
nating the length of the fatty acid chain. This may find its
applications in a wider range of diseases, such as hyperlipid-
aemia or obesity. Additionally, we also observed an increase
in expression of the ATP5O subunit of ATP synthase, along-
side a decrease in expression of NDUFC1, encoding a super-
numerary subunit of complex I, the precise function of which
remains unknown. This may reflect the fact that fatty acid
metabolism bypasses complex I in the respiratory chain. The
genes involved in glucose metabolism which were downreg-
ulated include PCK2 which encodes the enzyme phospho-
enolpyruvate carboxykinase, a key enzyme of gluconeogene-
sis. Additionally, we also observed an increase in expression
levels of PDK4 and PDK3, which encode the pyruvate
dehydrogenase kinase, an enzyme which inhibits pyruvate
dehydrogenase — an essential link between glycolysis and
the TCA cycle (Fig. 4). Finally, the observation that expres-
sion of genes associated with gluconeogenesis was decreased,
whilst that of genes associated with fatty acid oxidation was
increased, suggests the possibility that stress signalling may
be at play, possibly mediated by AMPK (Hardie et al 2015).
This would be an interesting avenue for further investigations.
We conclude that supplementation of fibroblast cells with
C10 has pleiotropic effects on mitochondrial function through
targeting the PPAR-γ receptor, and thus potentially increasing
mitochondrial biogenesis as well as increasing cellular resis-
tance to oxidative stress. Based on these preliminary findings,
we suggest that this therapy should now be further investigat-
ed in mouse models of mitochondrial disease. Our results also
highlight the importance of genetically and phenotypically
matched cohorts when studying treatments for mitochondrial
diseases, and suggest that not every mitochondrial patient will
benefit from the same type of treatment. Furthermore, the
assay methods described here could be utilised to identify
suitable patients for further investigation of the efficacy of
C10 therapy in a clinical trial, in a ‘personalised medicine’
approach.
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